International Journal of
eISSN: 2574-8084
Submit manuscript...
Research Article Volume 12 Issue 4
High-biodiversity probiotic promotes liver fibrosis regression; implications for radiotherapy
Renee Badolato, Marco Ruggiero
Received: August 20, 2025 | Published: September 12, 2025
Citation: Badolato R, Ruggiero M. High-biodiversity probiotic promotes liver fibrosis regression; implications for radiotherapy. Int J Radiol Radiat Ther. 2025;12(4):96-99. DOI: 10.15406/ijrrt.2025.12.00430
Abstract
Liver fibrosis, a progressive accumulation of extracellular matrix proteins, is a common pathological outcome of chronic liver diseases and a significant long-term complication of radiation-induced liver disease (RILD) following oncological radiotherapy. This case report details the notable improvement in an 83-year-old male patient with established liver fibrosis, objectively measured by elastography ( FibroScan), who received daily supplementation with a high-biodiversity probiotic (Freeze Dried Bravo probiotic). After approximately six months, the patient’s liver stiffness score significantly decreased from 7.6 kPa (moderate fibrosis, F2) to 3.6 kPa (absence of fibrosis, F0). This improvement was not confined to the liver alone. Concurrently, a remarkable trend toward normalization was observed in several key blood parameters, including Mean Corpuscular Hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), glycemia, serum creatine, and Blood Urea Nitrogen (BUN). A significant decrease in the White Blood Cell (WBC) count also suggests a reduction in systemic inflammation. The hepatic improvement is consistent with a prior observation presented in 2013 by one of the authors, involving a severe fibrosis case that regressed with probiotic use. We hypothesize that the unique biodiversity and postbiotic richness of Bravo probiotic, possessing immunomodulatory and detoxifying properties, contributed to these systemic and anti-fibrotic effects by improving gut barrier integrity and reducing inflammation. While acknowledging the limitations of a single case report, these findings suggest a promising non-pharmacological strategy for managing liver fibrosis across various etiologies, including potential applications in mitigating RILD. Further rigorous clinical trials are warranted to validate these observations and elucidate the underlying mechanisms.
Keywords: liver fibrosis, probiotic, elastography, fibroscan, gut-liver axis, metabolic improvement
©2025 Badolato, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.